Protein Kinase C Epsilon Type – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) – Pipeline Review, H2 2020’, provides in depth analysis on Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Cardiovascular, Genetic Disorders, Infectious Disease, Oncology and Ophthalmology under development targeting Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)

– The report reviews Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics and enlists all their major and minor projects

– The report assesses Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

BryoLogyx Inc

CHS Pharma Inc

Neurotrope Bioscience Inc

VM Discovery Inc

Young Therapeutics LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC

2.7.11.13) - Overview

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC

2.7.11.13) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC

2.7.11.13) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC

2.7.11.13) - Companies Involved in Therapeutics Development

BryoLogyx Inc

CHS Pharma Inc

Neurotrope Bioscience Inc

VM Discovery Inc

Young Therapeutics LLC

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC

2.7.11.13) - Drug Profiles

Bryostatin-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Epsilon PKC for Ischemic Stroke - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate PKC Epsilon for Neurology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate PRKCE for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PRKCE for HIV and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sulindac - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VMD-2202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YT-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC

2.7.11.13) - Dormant Products

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC

2.7.11.13) - Discontinued Products

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC

2.7.11.13) - Product Development Milestones

Featured News & Press Releases

Oct 13, 2020: BryoLogyx announces completion of world’s first GMP synthesis of bryostatin-1

Oct 07, 2020: Neurotrope begins Phase II trial of Alzheimer's drug candidate

Aug 04, 2020: BryoLogyx announces cooperative research and development agreement for Bryostatin-1 with National Cancer Institute

Jul 30, 2020: Neurotrope Bioscience announces agreement with worldwide clinical trials, to conduct ongoing phase 2 study of Bryostatin-1, partially funded by NIH, for Alzheimer's Disease

Jun 10, 2020: Neurotrope announces strategic partnership with BryoLogyx for supply of synthetic Bryostatin-1 and continuation of the National Cancer Institute (NCI) trial for childhood leukemia

May 28, 2020: Neurotrope launches new long-term clinical trial of Bryostatin with the National Institutes of Health for the treatment of patients with Alzheimer's Disease

Jan 22, 2020: Neurotrope provides corporate update after completing Bryostatin-1 data analysis for advanced Alzheimer's disease trial

Sep 10, 2019: Neurotrope Alzheimer’s Phase II trial fails to meet endpoints

Aug 13, 2019: Neurotrope announces publication highlighting the potential of bryostatin as a unique neurorestorative therapy

Jul 15, 2019: Neurotrope concludes data collection in confirmatory phase 2 clinical trial of moderately severe to severe Alzheimer's Disease

Jul 11, 2019: Neurotrope to present at the Alzheimer's Association International Conference; Neurotrope President and Chief Scientific Officer, Dr. Daniel L. Alkon, to Receive Cure Coin Award; Design of Confirmatory Phase 2 Trial to be Presented

Jun 03, 2019: Neurotrope's president and chief scientific officer to present at the Alzheimer's Solutions Conference at The University of the Sciences in Philadelphia, PA on June 3rd, 2019

Mar 21, 2019: Neurotrope CEO statement on development of Bryostatin

Mar 14, 2019: Neurotrope doses last patient in Alzheimer’s trial

Dec 17, 2018: Neurotrope announces publication of phase 2 study of Bryostatin-1 in moderate to severe alzheimer's disease in the Journal of Alzheimer's Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Indication, H2 2020

Number of Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Pipeline by BryoLogyx Inc, H2 2020

Pipeline by CHS Pharma Inc, H2 2020

Pipeline by Neurotrope Bioscience Inc, H2 2020

Pipeline by VM Discovery Inc, H2 2020

Pipeline by Young Therapeutics LLC, H2 2020

Dormant Projects, H2 2020

Discontinued Products, H2 2020

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports